valsartan has been researched along with Encapsulating Peritoneal Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Y; Jiang, CM; Jin, B; Liu, J; Shao, QY; Sun, C; Xia, YY; Xu, PF; Zhang, M; Zhang, QY; Zhu, W | 1 |
| Chiu, YH; Hsu, BG; Ke, CY; Lee, CJ; Lin, NT; Subeq, YM | 1 |
2 other study(ies) available for valsartan and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
Valsartan ameliorates high glucose-induced peritoneal fibrosis by blocking mTORC1 signaling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dialysis Solutions; Glucose; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Signal Transduction; Valsartan | 2020 |
Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats.
Topics: Animals; Blood Pressure; Chlorhexidine; Glucose; Heart Rate; Immunohistochemistry; Liver Cirrhosis; Male; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Protective Agents; Rats; Rats, Sprague-Dawley; Staining and Labeling; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2011 |